Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01499420 · ClinicalTrials.gov registry record · Phase 2
A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients
A Phase 2 study, sponsored by CSL Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01499420 is a Phase 2 study that has completed, run by CSL Limited. The registered enrollment target is 45 participants.
The verdict
NCT01499420, a Phase 2 study, has completed, sponsored by CSL Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Reconstituted high density lipoprotein used in patients with acute coronary syndrome (ACS) may reduce atherosclerotic plaque burden, thereby reducing the risk of recurrent cardiovascular events. This study is a multi-center, randomized, placebo-controlled, single ascending dose study in patients with stable atherothrombotic disease in whom the safety and pharmacokinetic profile of CSL112 will be assessed.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CSL112 (reconstituted high density lipoprotein)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01499420
The ClinicalTrials.gov registry entry for NCT01499420 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01499420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01499420 about?
NCT01499420 is a clinical study titled "A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients". Reconstituted high density lipoprotein used in patients with acute coronary syndrome (ACS) may reduce atherosclerotic plaque burden, thereby reducing the risk of recurrent cardiovascular events. This study is a multi-center, randomized, placebo-controlled, single ascending dose study in patients wit...
What is the current status of trial NCT01499420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2012-02. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01499420?
The interventions under investigation include: Placebo (BIOLOGICAL), CSL112 (reconstituted high density lipoprotein) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01499420?
This trial is sponsored by CSL Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.